The Competition and Markets Authority (CMA) has concluded, following new evidence, that extra remedies in London's private healthcare market such as price controls would not be proportionate as part of its investigation into the UK private healthcare market.
Two of the CMA members dissented from this decision. Insurer Bupa described the final decision from the watchdog as "extraordinary" and argued it "had failed to find a solution." The Competition Commission, a predecessor body of the CMA, started a market investigation into private healthcare in April 2012, which reported in April 2014, immediately after the establishment of the CMA. The report concluded that certain features of the markets for privately-funded healthcare services were leading to adverse effects on competition (AEC). A number of remedies introduced in the report,...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
